ImmunityBio (IBRX) shares soared 26.4% in the last trading session to close at $5.32. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.Last week, the company announced the dosing of the first patient in a phase I study evaluating its CAR-NK cell therapy, CD19 t-haNK, for treating relapsed B-cell non-Hodgkin lymphoma. This might have driven the share price rally.This immunotherapy company is expecte ...

Core Insights - ImmunityBio (NASDAQ: IBRX) is focusing on the commercial launch of ANKTIVA (N-803) for treating BCG-unresponsive non-muscle invasive bladder cancer, indicating a strategic positioning for rapid growth in the healthcare sector [2]. Group 1 - The company is leveraging data analytics, technical analysis, and clinical data to manage a diverse portfolio of potential multi-bagger investments in healthcare [1]. - The investment group Compounding Healthcare offers several model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among investors [2]. - The focus of the investment strategy is on innovative companies that are developing breakthrough therapies and pharmaceuticals, particularly those with catalysts for potential acquisitions [2].

ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.65%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.16 per share when it actually produced a loss of $0.20, delivering a surprise of -25%. Over the last four quarters, the company h ...

NEW YORK, July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. Why Your Participation Matters: For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. SOURCE Kuehn Law, PLLC If you own ...

Anktiva, in combination with Bacillus Calmette-Guérin (BCG), got FDA approval in April 2024 for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Year to date, shares of IBRX have rallied 44.8% against the industry's 4.1% decline. Patients were treated for up to 37 months, with their tumor status regularly assessed through cystoscopy and urine cytology. The monitoring will continue for up to five years f ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37507 _____________________________________ IMMUNITYBIO, INC. (Exact name of registrant as specified in its c ...

ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021. It is up by over 770% from its lowest point in 2023, giving it a market cap of almost $6 billion.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Future acquisition likely?Copy link to sectionImmunityBio shares have been in a strong ...

ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over 20% in the extended session.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.FDA approves ANKTIVACopy link to sectionThis rally makes ImmunityBio one of the best-performing stocks in Wall Street as it has risen by over 100% in the past 12 months. The jump ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Commission file number: 001-37507 _____________________________________ IMMUNITYBIO, INC. (Exact name of registrant as specified in its charter) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37507 _____________________________________ IMMUNITYBIO, INC. (Exact name of registrant as specified in i ...